PF-07104091 |
カタログ番号GC62660 |
PF-07104091は、CDK2/cyclin E1阻害剤であり、キナーゼのサイクリン結合活性化状態をターゲットとする選択的なATPサイト阻害剤です[1]。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2460249-19-6
Sample solution is provided at 25 µL, 10mM.
PF-07104091 is a CDK2/cyclin E1 inhibitor, a selective ATP-site inhibitor targeting the cyclin-bound activated state of the kinase [1]. PF-07104091(Example 13) inhibited CDK2/cyclin E1, GSK3β, CDK1/cyclin A2, CDK4/cyclin D1, CDK6/cyclin D3 and CDK9, with Kis of 1.16, 537.81, 110, 238, 465 and 117 nM, respectively. PF-07104091 has anti-tumor activity for cyclin E1-amplified cancers. [1].
PF-07104091 inhibited T47D and KPL1 cells with IC50s of 0.785 and 0.603 µM, respectively [2].
The combination of abemaciclib and PF-07104091decreased T47D and KPL1 cells survival compared to either single agent [2].
References:
[1]. Behenna, D. C.; Freeman-Cook, K. D.; Hoffman, R. L.; Nagata, A.; Ninkovic, S.; Sutton, S. C. Preparation of aminopyrazolylcyclopentyl carbamate derivatives for use as CDK2 inhibitors. WO 2020157652, 2020.
[2]. Gharbi S I, Pelletier L A, Espada A, et al. Crystal structure of active CDK4-cyclin D and mechanistic basis for abemaciclib efficacy[J]. npj Breast Cancer, 2022, 8(1): 126.
Average Rating: 5
(Based on Reviews and 17 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *